Tower Research Capital (TRC)’s OptimizeRx OPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11.5K Sell
1,829
-318
-15% -$2.95K ﹤0.01% 3838
2025
Q4
$26.3K Buy
2,147
+1,156
+117% +$18.9K ﹤0.01% 2896
2025
Q3
$20.3K Sell
991
-1,737
-64% -$27.6K ﹤0.01% 3294
2025
Q2
$36.8K Buy
2,728
+1,515
+125% +$16.6K ﹤0.01% 3230
2025
Q1
$10.5K Sell
1,213
-688
-36% -$4.21K ﹤0.01% 3632
2024
Q4
$9.24K Buy
1,901
+964
+103% +$5.39K ﹤0.01% 3922
2024
Q3
$7.23K Sell
937
-10,788
-92% -$95.9K ﹤0.01% 4064
2024
Q2
$117K Buy
11,725
+11,223
+2,236% +$123K ﹤0.01% 2462
2024
Q1
$6.1K Sell
502
-6,263
-93% -$90.8K ﹤0.01% 4433
2023
Q4
$96.8K Buy
6,765
+5,432
+408% +$52.1K ﹤0.01% 2664
2023
Q3
$10.4K Buy
1,333
+659
+98% +$7.17K ﹤0.01% 4117
2023
Q2
$9.63K Buy
674
+59
+10% +$840 ﹤0.01% 4246
2023
Q1
$9K Sell
615
-20,017
-97% -$335K ﹤0.01% 4522
2022
Q4
$347K Buy
20,632
+19,364
+1,527% +$335K 0.01% 925
2022
Q3
$19K Sell
1,268
-5,347
-81% -$106K ﹤0.01% 3981
2022
Q2
$181K Buy
6,615
+6,137
+1,284% +$182K ﹤0.01% 1840
2022
Q1
$18K Buy
478
+75
+19% +$3.32K ﹤0.01% 3640
2021
Q4
$25K Sell
403
-540
-57% -$40.9K ﹤0.01% 3430
2021
Q3
$81K Buy
943
+350
+59% +$22K ﹤0.01% 2578
2021
Q2
$37K Sell
593
-478
-45% -$24.3K ﹤0.01% 3282
2021
Q1
$52K Sell
1,071
-3,146
-75% -$152K ﹤0.01% 3091
2020
Q4
$131K Sell
4,217
-11,376
-73% -$279K ﹤0.01% 2102
2020
Q3
$325K Buy
15,593
+12,613
+423% +$217K ﹤0.01% 2113
2020
Q2
$39K Buy
2,980
+2,730
+1,092% +$29.7K ﹤0.01% 3249
2020
Q1
$2K Buy
250
+149
+148% +$1.41K ﹤0.01% 2613
2019
Q4
$1K Sell
101
-992
-91% -$11.2K ﹤0.01% 3299
2019
Q3
$16K Buy
1,093
+892
+444% +$13.8K ﹤0.01% 2623
2019
Q2
$3K Sell
201
-71
-26% -$959 ﹤0.01% 3154
2019
Q1
$3K Sell
272
-4,576
-94% -$59.5K ﹤0.01% 3308
2018
Q4
$53K Buy
4,848
+3,731
+334% +$55.2K ﹤0.01% 1253
2018
Q3
$20K Buy
+1,117
New +$14.1K ﹤0.01% 2347

Other funds holding OPRX

Tower Research Capital (TRC)'s OPRX Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its OptimizeRx (OPRX) stake by 15% in Q1 2026, selling an estimated $2.95K and leaving 1,829 shares worth $11.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3838.

Tower Research Capital (TRC) first reported a position in OPRX in Q3 2018 and has held it in 31 quarters since. The position peaked at $347K in Q4 2022. 127 funds tracked by Wall St. Rank hold OPRX as of Q1 2026.

  • Tower Research Capital (TRC) held 1,829 shares of OptimizeRx worth $11.5K as of Q1 2026.
  • Tower Research Capital (TRC) sold 318 OptimizeRx shares in Q1 2026, an estimated $2.95K.
  • OptimizeRx made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3838 holding.
  • Tower Research Capital (TRC) first reported a position in OptimizeRx in Q3 2018 and has held it in 31 quarters since.
  • Tower Research Capital (TRC)'s OptimizeRx position peaked at $347K in Q4 2022.
  • 127 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.